Prostate Cancer Registries: Current Status and Future Directions

Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, Robert Jeffrey Karnes, Michael J. Leveridge, Kim Moretti, Declan G. Murphy, David F. Penson, David C. Miller

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Context: Disease-specific registries that enroll a considerable number of patients play a major role in prostate cancer (PCa) research. Objective: To evaluate available registries, describe their strengths and limitations, and discuss the potential future role of PCa registries in outcomes research. Evidence acquisition: We performed a literature review of the Medline, Embase, and Web of Science databases. The search strategy included the terms prostate cancer, outcomes, statistical approaches, population-based cohorts, registries of outcomes, and epidemiological studies, alone or in combination. We limited our search to studies published between January 2005 and January 2015. Evidence synthesis: Several population-based and prospective disease-specific registries are currently available for prostate cancer. Studies performed using these data sources provide important information on incidence and mortality, disease characteristics at presentation, risk factors, trends in utilization of health care services, disparities in access to treatment, quality of care, long-term oncologic and health-related quality of life outcomes, and costs associated with management of the disease. Although data from these registries have some limitations, statistical methods are available that can address certain biases and increase the internal and external validity of such analyses. In the future, improvements in data quality, collection of tissue samples, and the availability of data feedback to health care providers will increase the relevance of studies built on population-based and disease-specific registries. Conclusions: The strengths and limitations of PCa registries should be carefully considered when planning studies using these databases. Although randomized controlled trials still provide the highest level of evidence, large registries play an important and growing role in advancing PCa research and care. Patient summary: Several population-based and prospective disease-specific registries for prostate cancer are currently available. Analyses of data from these registries yield information that is clinically relevant for the management of patients with prostate cancer. Although randomized controlled studies still provide the highest level of evidence, analyses of data from population-based and prospective disease-specific registries provide clinically relevant information for the management of patients with prostate cancer.

Original languageEnglish (US)
JournalEuropean Urology
DOIs
StateAccepted/In press - 2015

Fingerprint

Registries
Prostatic Neoplasms
Population
Direction compound
Healthcare Disparities
Outcome Assessment (Health Care)
Databases
Information Management
Quality of Health Care
Information Storage and Retrieval
Disease Management
Research
Health Personnel
Health Services
Epidemiologic Studies
Randomized Controlled Trials
Quality of Life
Costs and Cost Analysis
Mortality
Incidence

Keywords

  • Disease-specific outcomes
  • Epidemiology
  • Population-based
  • Prospective registries
  • Prostate cancer
  • Statistical approaches

ASJC Scopus subject areas

  • Urology

Cite this

Gandaglia, G., Bray, F., Cooperberg, M. R., Karnes, R. J., Leveridge, M. J., Moretti, K., ... Miller, D. C. (Accepted/In press). Prostate Cancer Registries: Current Status and Future Directions. European Urology. https://doi.org/10.1016/j.eururo.2015.05.046

Prostate Cancer Registries : Current Status and Future Directions. / Gandaglia, Giorgio; Bray, Freddie; Cooperberg, Matthew R.; Karnes, Robert Jeffrey; Leveridge, Michael J.; Moretti, Kim; Murphy, Declan G.; Penson, David F.; Miller, David C.

In: European Urology, 2015.

Research output: Contribution to journalArticle

Gandaglia, G, Bray, F, Cooperberg, MR, Karnes, RJ, Leveridge, MJ, Moretti, K, Murphy, DG, Penson, DF & Miller, DC 2015, 'Prostate Cancer Registries: Current Status and Future Directions', European Urology. https://doi.org/10.1016/j.eururo.2015.05.046
Gandaglia, Giorgio ; Bray, Freddie ; Cooperberg, Matthew R. ; Karnes, Robert Jeffrey ; Leveridge, Michael J. ; Moretti, Kim ; Murphy, Declan G. ; Penson, David F. ; Miller, David C. / Prostate Cancer Registries : Current Status and Future Directions. In: European Urology. 2015.
@article{047a5d76d2754e94ae280c4bcc96ffd2,
title = "Prostate Cancer Registries: Current Status and Future Directions",
abstract = "Context: Disease-specific registries that enroll a considerable number of patients play a major role in prostate cancer (PCa) research. Objective: To evaluate available registries, describe their strengths and limitations, and discuss the potential future role of PCa registries in outcomes research. Evidence acquisition: We performed a literature review of the Medline, Embase, and Web of Science databases. The search strategy included the terms prostate cancer, outcomes, statistical approaches, population-based cohorts, registries of outcomes, and epidemiological studies, alone or in combination. We limited our search to studies published between January 2005 and January 2015. Evidence synthesis: Several population-based and prospective disease-specific registries are currently available for prostate cancer. Studies performed using these data sources provide important information on incidence and mortality, disease characteristics at presentation, risk factors, trends in utilization of health care services, disparities in access to treatment, quality of care, long-term oncologic and health-related quality of life outcomes, and costs associated with management of the disease. Although data from these registries have some limitations, statistical methods are available that can address certain biases and increase the internal and external validity of such analyses. In the future, improvements in data quality, collection of tissue samples, and the availability of data feedback to health care providers will increase the relevance of studies built on population-based and disease-specific registries. Conclusions: The strengths and limitations of PCa registries should be carefully considered when planning studies using these databases. Although randomized controlled trials still provide the highest level of evidence, large registries play an important and growing role in advancing PCa research and care. Patient summary: Several population-based and prospective disease-specific registries for prostate cancer are currently available. Analyses of data from these registries yield information that is clinically relevant for the management of patients with prostate cancer. Although randomized controlled studies still provide the highest level of evidence, analyses of data from population-based and prospective disease-specific registries provide clinically relevant information for the management of patients with prostate cancer.",
keywords = "Disease-specific outcomes, Epidemiology, Population-based, Prospective registries, Prostate cancer, Statistical approaches",
author = "Giorgio Gandaglia and Freddie Bray and Cooperberg, {Matthew R.} and Karnes, {Robert Jeffrey} and Leveridge, {Michael J.} and Kim Moretti and Murphy, {Declan G.} and Penson, {David F.} and Miller, {David C.}",
year = "2015",
doi = "10.1016/j.eururo.2015.05.046",
language = "English (US)",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",

}

TY - JOUR

T1 - Prostate Cancer Registries

T2 - Current Status and Future Directions

AU - Gandaglia, Giorgio

AU - Bray, Freddie

AU - Cooperberg, Matthew R.

AU - Karnes, Robert Jeffrey

AU - Leveridge, Michael J.

AU - Moretti, Kim

AU - Murphy, Declan G.

AU - Penson, David F.

AU - Miller, David C.

PY - 2015

Y1 - 2015

N2 - Context: Disease-specific registries that enroll a considerable number of patients play a major role in prostate cancer (PCa) research. Objective: To evaluate available registries, describe their strengths and limitations, and discuss the potential future role of PCa registries in outcomes research. Evidence acquisition: We performed a literature review of the Medline, Embase, and Web of Science databases. The search strategy included the terms prostate cancer, outcomes, statistical approaches, population-based cohorts, registries of outcomes, and epidemiological studies, alone or in combination. We limited our search to studies published between January 2005 and January 2015. Evidence synthesis: Several population-based and prospective disease-specific registries are currently available for prostate cancer. Studies performed using these data sources provide important information on incidence and mortality, disease characteristics at presentation, risk factors, trends in utilization of health care services, disparities in access to treatment, quality of care, long-term oncologic and health-related quality of life outcomes, and costs associated with management of the disease. Although data from these registries have some limitations, statistical methods are available that can address certain biases and increase the internal and external validity of such analyses. In the future, improvements in data quality, collection of tissue samples, and the availability of data feedback to health care providers will increase the relevance of studies built on population-based and disease-specific registries. Conclusions: The strengths and limitations of PCa registries should be carefully considered when planning studies using these databases. Although randomized controlled trials still provide the highest level of evidence, large registries play an important and growing role in advancing PCa research and care. Patient summary: Several population-based and prospective disease-specific registries for prostate cancer are currently available. Analyses of data from these registries yield information that is clinically relevant for the management of patients with prostate cancer. Although randomized controlled studies still provide the highest level of evidence, analyses of data from population-based and prospective disease-specific registries provide clinically relevant information for the management of patients with prostate cancer.

AB - Context: Disease-specific registries that enroll a considerable number of patients play a major role in prostate cancer (PCa) research. Objective: To evaluate available registries, describe their strengths and limitations, and discuss the potential future role of PCa registries in outcomes research. Evidence acquisition: We performed a literature review of the Medline, Embase, and Web of Science databases. The search strategy included the terms prostate cancer, outcomes, statistical approaches, population-based cohorts, registries of outcomes, and epidemiological studies, alone or in combination. We limited our search to studies published between January 2005 and January 2015. Evidence synthesis: Several population-based and prospective disease-specific registries are currently available for prostate cancer. Studies performed using these data sources provide important information on incidence and mortality, disease characteristics at presentation, risk factors, trends in utilization of health care services, disparities in access to treatment, quality of care, long-term oncologic and health-related quality of life outcomes, and costs associated with management of the disease. Although data from these registries have some limitations, statistical methods are available that can address certain biases and increase the internal and external validity of such analyses. In the future, improvements in data quality, collection of tissue samples, and the availability of data feedback to health care providers will increase the relevance of studies built on population-based and disease-specific registries. Conclusions: The strengths and limitations of PCa registries should be carefully considered when planning studies using these databases. Although randomized controlled trials still provide the highest level of evidence, large registries play an important and growing role in advancing PCa research and care. Patient summary: Several population-based and prospective disease-specific registries for prostate cancer are currently available. Analyses of data from these registries yield information that is clinically relevant for the management of patients with prostate cancer. Although randomized controlled studies still provide the highest level of evidence, analyses of data from population-based and prospective disease-specific registries provide clinically relevant information for the management of patients with prostate cancer.

KW - Disease-specific outcomes

KW - Epidemiology

KW - Population-based

KW - Prospective registries

KW - Prostate cancer

KW - Statistical approaches

UR - http://www.scopus.com/inward/record.url?scp=84930326701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930326701&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2015.05.046

DO - 10.1016/j.eururo.2015.05.046

M3 - Article

C2 - 26056070

AN - SCOPUS:84930326701

JO - European Urology

JF - European Urology

SN - 0302-2838

ER -